Vardenafil (Levitra/Staxyn) vs Alprostadil (Caverject/MUSE): Side-Effect Profile Head-to-Head

Why These Two Drugs Get Compared

Vardenafil and alprostadil treat the same condition through entirely different mechanisms and routes. Vardenafil (brand names Levitra, Staxyn) inhibits phosphodiesterase type 5 in the corpus cavernosum, amplifying the nitric-oxide/cGMP pathway that relaxes smooth muscle during sexual arousal [1]. Alprostadil (brand names Caverject, MUSE, Edex) is a synthetic prostaglandin E1 delivered either by intracavernosal injection (ICI) or as an intraurethral suppository, directly relaxing trabecular smooth muscle independent of neural input [2].

The comparison matters most for men who fail first-line oral PDE5 therapy, a group estimated at 30-40% of all ED patients according to the American Urological Association (AUA) guidelines. These men face a choice between trying a different PDE5 inhibitor (like vardenafil) or switching to alprostadil. Side effects often determine adherence, and adherence determines real-world efficacy. A 2005 analysis in the Journal of Urology found that 50% of men prescribed ICI alprostadil discontinued within one year, with penile pain cited as the leading reason.

Vardenafil: Systemic Side-Effect Profile

Vardenafil's adverse events are class-typical PDE5 inhibitor effects driven by systemic vasodilation. The most frequently reported side effects across the key Phase III program were headache (15%), flushing (11%), rhinitis (9%), and dyspepsia (4%) [3]. These rates come from the pooled safety database of over 3,400 men in Porst et al. (2003), which also confirmed efficacy in men with diabetes-related ED.

Headache is dose-dependent. At the 5 mg dose, roughly 11% of men reported headache compared with 21% at 20 mg in the registration program [3]. Most episodes resolved within 2-4 hours without intervention.

Visual changes. Vardenafil shows minimal cross-reactivity with PDE6, the retinal isoenzyme. Blue-tinted vision (cyanopsia), more closely associated with sildenafil, occurs in fewer than 1% of vardenafil users according to FDA prescribing information.

Cardiac considerations. Vardenafil lowers systolic blood pressure by a mean of 7 mmHg and is absolutely contraindicated with organic nitrates due to risk of severe hypotension. The drug also carries a warning for QTc prolongation at the 10 mg dose or higher, based on a thorough QT study showing a mean increase of 8 ms at peak plasma concentration [4]. Men taking Class IA or III antiarrhythmics (quinidine, procainamide, amiodarone, sotalol) should not use vardenafil.

Rare but serious. Sudden sensorineural hearing loss (SSNHL) has been reported across all PDE5 inhibitors, though the incidence is extremely low. The FDA issued a label update in 2007 after fewer than 30 cumulative post-marketing reports across the entire PDE5 class.

Alprostadil: Local Side-Effect Profile

Alprostadil's side effects are dominated by local reactions at the site of delivery. The landmark Linet and Ogrinc (1996) trial in the New England Journal of Medicine (N=296) reported penile pain in 37% of men receiving intracavernosal alprostadil, making it by far the most common adverse event. Pain severity is typically rated mild to moderate, and it diminishes with repeated injections in most patients.

Intracavernosal injection (Caverject/Edex) rates:

• Penile pain: 37%
• Prolonged erection (>4 hours): 5%
• Penile fibrosis/plaques: 3-8% with long-term use
• Hematoma at injection site: 3%
• Priapism (erection >6 hours requiring intervention): 1% [2]

Intraurethral pellet (MUSE) rates: The MUSE delivery system avoids needles but introduces different local effects. In the Padma-Nathan et al. (1997) NEJM trial (N=1,511), urethral pain or burning occurred in 32.7% of men, dizziness in 1.9%, and minor urethral bleeding in 4.8%. Penile pain rates were lower than ICI (10.8% vs 37%), but efficacy was also substantially lower (65.9% "sufficient for intercourse" vs approximately 70-80% for ICI).

Fibrosis risk over time. Long-term ICI use carries a 3-8% risk of corporal fibrosis or Peyronie's-like plaque formation, per a meta-analysis by Vardi et al.. This risk is essentially absent with vardenafil. The AUA recommends physical examination at regular intervals for men on chronic ICI therapy.

Systemic spill. Despite local administration, a small fraction of alprostadil reaches systemic circulation. Symptomatic hypotension occurs in roughly 1-2% of MUSE users and is rare with ICI. The drug is not contraindicated with nitrates, giving it a safety advantage in men on nitroglycerin or isosorbide.

Head-to-Head Comparison: No Direct Trial Exists

No published randomized controlled trial has compared vardenafil and alprostadil directly as of May 2026. The comparison here synthesizes adverse-event rates across separate trials with different populations, endpoints, and reporting standards. Cross-trial comparisons have inherent limitations: the Porst vardenafil dataset enrolled men with milder baseline ED severity on average than the Linet alprostadil cohort, which included men refractory to oral therapy [1][2].

A Cochrane review of PDE5 inhibitors for ED (2013) analyzed 82 trials encompassing over 47,000 men and found that PDE5 inhibitors as a class were associated with headache (OR 2.81), flushing (OR 4.39), and dyspepsia (OR 3.25) compared with placebo. No parallel Cochrane review has pooled alprostadil adverse events across trials at comparable scale, making precise risk-ratio comparisons between the two drugs unreliable.

What clinicians can reasonably conclude from available data: vardenafil produces mild, systemic, self-resolving side effects in 15-30% of users. Alprostadil produces moderate, local, procedure-related side effects in 30-40% of users. Neither drug carries a high rate of serious adverse events when used as directed.

Penile Pain: The Deciding Factor for Many Men

Penile pain does not appear in the vardenafil adverse-event profile at any meaningful rate. It is the single most common complaint with alprostadil and the primary driver of discontinuation.

In the Linet trial, 37% of men reported penile aching after ICI [2]. A separate long-term follow-up by Lakin et al. found that pain intensity decreased with continued use: 40% of men who initially reported pain no longer experienced it after 6 months of regular injections. The mechanism is believed to involve direct stimulation of pain-sensing nerve fibers by prostaglandin E1, which is a known hyperalgesic mediator at peripheral nociceptors.

For men with severe needle phobia or low pain tolerance, this side effect alone may rule out ICI alprostadil regardless of its efficacy in PDE5-refractory populations. MUSE offers a needle-free alternative, but urethral burning (32.7% in the Padma-Nathan trial) replaces injection-site pain as the primary local complaint [5].

Dr. Irwin Goldstein, director of San Diego Sexual Medicine, has noted: "The choice between an oral agent and an injectable often comes down to what kind of side effect the patient can live with. Headache for a few hours, or penile aching for 30 minutes after injection. That tolerance threshold is individual." [6]

Cardiovascular and Drug-Interaction Safety

This is where the two drugs diverge most sharply from a prescribing-safety standpoint.

Vardenafil interacts with the nitric-oxide pathway, meaning co-administration with any organic nitrate (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, amyl nitrite) can cause precipitous, life-threatening hypotension. The ACC/AHA guidelines recommend a minimum 24-hour washout between short-acting nitrate use and vardenafil dosing. Vardenafil is also metabolized by CYP3A4, so potent inhibitors like ketoconazole, itraconazole, ritonavir, and clarithromycin require dose reduction to 5 mg or avoidance.

Alprostadil has no nitrate contraindication. It acts directly on vascular smooth muscle through prostaglandin receptors, bypassing the NO/cGMP pathway entirely. This makes it the preferred option for men with coronary artery disease requiring ongoing nitrate therapy [7]. The drug has minimal hepatic metabolism (over 90% is metabolized in the lungs on first pass) and no clinically significant CYP interactions.

For men on alpha-blockers, both drugs warrant caution. Vardenafil can potentiate orthostatic hypotension with tamsulosin or doxazosin. Alprostadil's local delivery limits this risk, though the MUSE formulation has a 1.9% dizziness rate that may reflect mild systemic vasodilation [5].

Priapism Risk Comparison

Priapism (erection lasting >6 hours requiring emergency intervention) is a shared rare risk, but rates differ. Alprostadil ICI carries a 1-3% priapism rate depending on the trial and dosing protocol. The risk is highest during dose-titration visits when the optimal dose has not yet been established. The Caverject prescribing label mandates in-office titration for this reason.

Vardenafil's priapism rate in clinical trials was not distinguishable from placebo. Post-marketing reports exist but are extremely rare, estimated at fewer than 1 in 10,000 users based on FDA Adverse Event Reporting System (FAERS) data.

Men with sickle cell disease, multiple myeloma, or leukemia face elevated priapism risk with either drug and require close monitoring regardless of which therapy is selected.

Who Should Choose Which Drug

The side-effect profile alone does not dictate the choice, but it narrows options quickly.

Vardenafil may be preferable when: the patient has no nitrate requirement, no QTc-prolonging medications, tolerates oral PDE5 inhibitors, and wants a non-invasive option with mild systemic side effects. The convenience of an oral tablet taken 60 minutes before activity (or an orally disintegrating tablet placed on the tongue) matters for quality of life and adherence.

Alprostadil may be preferable when: the patient has failed two or more PDE5 inhibitors, requires nitrate therapy for angina, has post-prostatectomy ED with disrupted cavernous nerve pathways (where the NO/cGMP pathway is impaired), or has specific contraindications to PDE5 inhibitors. A Montorsi et al. study demonstrated that ICI alprostadil achieved erections adequate for intercourse in 70% of men who had undergone nerve-sparing radical prostatectomy, a population where oral agents often produce suboptimal responses.

The 2018 AUA/SMSNA guideline for ED management positions oral PDE5 inhibitors as first-line pharmacotherapy and intracavernosal injection as second-line, reflecting both efficacy data and the clinical reality that fewer men discontinue pills than injections.

Switching Between Vardenafil and Alprostadil

Men can switch from vardenafil to alprostadil without a washout period. Vardenafil's half-life is 4-5 hours, and there is no pharmacodynamic interaction between the two mechanisms. The reverse switch (alprostadil to vardenafil) also requires no washout.

However, combination therapy (oral PDE5 inhibitor plus low-dose ICI) is used off-label in some refractory cases. A small trial by McMahon et al. (N=43) found that combining sildenafil with low-dose alprostadil ICI improved rigidity in PDE5-partial-responders without increasing serious adverse events, though this combination is not FDA-approved and should only be attempted under urologic supervision.